Study S003249

A Two-part, Non-randomized, Open-label, Parallel-group Study to Assess the Effect of Renal Impairment on the Pharmacokinetics and Safety of RO7795081 Following a Single Oral Dose of RO7795081

ClinicalTrials.gov record

Registration

Registration: NCT07741604
Study type: INTERVENTIONAL
Allocation: NON_RANDOMIZED
Phase: PHASE1
Masking: NONE
Status: RECRUITING
Enrollment: 60
Start: 2026-09-09
Primary completion: 2028-02-01
Lead sponsor: Hoffmann-La Roche
Conditions: Renal Impairment
Interventions: DRUG:RO7795081
Results posted: FALSE
Individual participant data sharing: NO

Registered primary outcomes

Maximum Plasma Concentration (Cmax) of RO7795081 [At prespecified timepoints from Day 1 to Day 14]
Area Under the Plasma Concentration-Time Curve (AUC) From Time 0 to the Last Measurable Concentration (AUClast) of RO7795081 [At prespecified timepoints from Day 1 to Day 14]
AUC From Time 0 to Infinity (AUCinf) of RO7795081 [At prespecified timepoints from Day 1 to Day 14]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.